Until now, pertuzumab in combination with trastuzumab and chemotherapy remains the only approved dual anti-HER2 regimen in the neoadjuvant setting for patients with HER2-positive early breast cancer [9, 10]. The gene discussed is ERBB2; the disease is breast carcinoma.